DARU Journal of Pharmaceutical Sciences

*DARU Journal of Pharmaceutical Sciences*
Discipline	Pharmaceutical sciences
Language	English
Edited by	Mohammad Abdollahi
Publication details
History	1990–present
Publisher	Springer Science+Business Media on behalf of Tehran University of Medical Sciences (Iran)
Frequency	Monthly
Open access	Hybrid
Impact factor	2.8 (2025)
Standard abbreviations;
ISO 4	DARU J. Pharm. Sci.
Indexing;
ISSN	1560-8115 (print); 2008-2231 (web);
OCLC no.	61283828
Links
	Journal homepage;

DARU Journal of Pharmaceutical Sciences is a hybrid open-access peer-reviewed medical journal that was established in 1990 in Iran. It covers all aspects of the pharmaceutical sciences. The editor-in-chief is Mohammad Abdollahi. From 2018 the journal is published by Springer Science+Business Media on behalf of Tehran University of Medical Sciences.

History

The journal was established as a Persian language journal in 1990. English abstracts were included in 1995, and the language changed to English in 1999. In 2012, the journal moved to open access with BioMed Central, which lasted until 2017.

Abstracting and indexing

The journal is indexed and abstracted in:

According to the Journal Citation Reports, the journal has a 2025 impact factor of 2.8.

Individual papers

In November 2025 Retraction Watch reported that the journal published a paper co-authored by the editor-in-chief that contained fabricated references, repetitive language and other characteristics of AI generated text. Springer Nature flagged the paper on unespecific concerns.

References

1 2 "Aims and scope". DARU Journal of Pharmaceutical Sciences. Retrieved 16 November 2025.
↑ Abdollahi, M (2012). "DARU Journal of Pharmaceutical Sciences; The 2012 report of Editor-in-Chief". DARU J Pharm Sci. 20 (1) 1. doi:10.1186/1560-8115-20-1. PMC 3514538. PMID 23226110.
↑ "DARU Journal of Pharmaceutical Sciences". 2025 Journal Citation Reports (Science ed.). Clarivate. 2026 – via Web of Science.
↑ Orrall, Avery; Travis, Kate (2025-11-21). "Springer Nature flags paper with fabricated reference to article (not) written by our cofounder". Retraction Watch. Archived from the original on 2025-11-25. Retrieved 2025-11-25.
↑ Aristidis Tsatsakis; Michael Aschner; Dimosthenis Sarigiannis; et al. (2025). "An expert criticism on post-publication peer review platforms: the case of pubpeer". DARU Journal of Pharmaceutical Sciences. 34 (1). doi:10.1007/s40199-025-00580-z. PMID 41233614. Wikidata Q137000226. {{Cite Q}}: Missing first/last names in Wikidata for Aristidis Tsatsakis, Michael Aschner, Dimosthenis Sarigiannis (help)

External links

Official website

[aims-1] 1 2 "Aims and scope". DARU Journal of Pharmaceutical Sciences. Retrieved 16 November 2025.

[2] Abdollahi, M (2012). "DARU Journal of Pharmaceutical Sciences; The 2012 report of Editor-in-Chief". DARU J Pharm Sci. 20 (1) 1. doi:10.1186/1560-8115-20-1. PMC 3514538. PMID 23226110.

[WoS-3] "DARU Journal of Pharmaceutical Sciences". 2025 Journal Citation Reports (Science ed.). Clarivate. 2026 – via Web of Science.

[4] Orrall, Avery; Travis, Kate (2025-11-21). "Springer Nature flags paper with fabricated reference to article (not) written by our cofounder". Retraction Watch. Archived from the original on 2025-11-25. Retrieved 2025-11-25.

[5] Aristidis Tsatsakis; Michael Aschner; Dimosthenis Sarigiannis; et al. (2025). "An expert criticism on post-publication peer review platforms: the case of pubpeer". DARU Journal of Pharmaceutical Sciences. 34 (1). doi:10.1007/s40199-025-00580-z. PMID 41233614. Wikidata Q137000226. {{Cite Q}}: Missing first/last names in Wikidata for Aristidis Tsatsakis, Michael Aschner, Dimosthenis Sarigiannis (help)